Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting

PHASE3CompletedINTERVENTIONAL
Enrollment

642

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

August 31, 2016

Conditions
Neoplasms
Interventions
DRUG

Thalidomide

100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1

DRUG

Placebo for thalidomide

Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1

DRUG

Palonosetron and Dexamethasone

Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.

Trial Locations (11)

110001

The First Hospital of China Medical University, Shenyang

110004

Shengjing Hospital of China Medical University, Shenyang

Unknown

Anshan Tumor Hospital, Anshan

Second Affiliated Hospital of Dalian Medical University, Dalian

The First Affiliated Hospital of Dalian Medical University, Dalian

The First Hospital of Liaoning Medical University, Jinzhou

Liaoyang Central Hospital, Liaoyang

Petrochemical General Hospital of Liaoyang city, Liaoyang

Third People's hospital Liaoyang, Liaoyang

General Hospital of Shenyang Military Region, Shenyang

Liaoning Tumor Hospital & Institute, Shenyang

All Listed Sponsors
collaborator

The First Hospital of Liaoning Medical University

UNKNOWN

collaborator

The First Affiliated Hospital of Dalian Medical University

OTHER

collaborator

The Second Affiliated Hospital of Dalian Medical University

OTHER

collaborator

Liaoning Cancer Hospital & Institute

OTHER

collaborator

Shengjing Hospital

OTHER

collaborator

General Hospital of Shenyang Military Region

OTHER

collaborator

Liaoyang Central Hospital

OTHER

collaborator

Third People's hospital Liaoyang

OTHER

collaborator

Petrochemical General Hospital of Liaoyang city

UNKNOWN

collaborator

Anshan Tumor Hospital

OTHER

lead

China Medical University, China

OTHER

NCT02203253 - Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting | Biotech Hunter | Biotech Hunter